These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

597 related items for PubMed ID: 16112045

  • 1. Renal response after high-dose melphalan and stem cell transplantation is a favorable marker in patients with primary systemic amyloidosis.
    Leung N, Dispenzieri A, Fervenza FC, Lacy MQ, Villicana R, Cavalcante JL, Gertz MA.
    Am J Kidney Dis; 2005 Aug; 46(2):270-7. PubMed ID: 16112045
    [Abstract] [Full Text] [Related]

  • 2. Severity of baseline proteinuria predicts renal response in immunoglobulin light chain-associated amyloidosis after autologous stem cell transplantation.
    Leung N, Dispenzieri A, Lacy MQ, Kumar SK, Hayman SR, Fervenza FC, Cha SS, Gertz MA.
    Clin J Am Soc Nephrol; 2007 May; 2(3):440-4. PubMed ID: 17699449
    [Abstract] [Full Text] [Related]

  • 3. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis.
    Sanchorawala V, Wright DG, Seldin DC, Dember LM, Finn K, Falk RH, Berk J, Quillen K, Skinner M.
    Bone Marrow Transplant; 2001 Oct; 28(7):637-42. PubMed ID: 11704785
    [Abstract] [Full Text] [Related]

  • 4. Long-term results of a risk-adapted approach to melphalan conditioning in autologous peripheral blood stem cell transplantation for primary (AL) amyloidosis.
    Perfetti V, Siena S, Palladini G, Bregni M, Di Nicola M, Obici L, Magni M, Brunetti L, Gianni AM, Merlini G.
    Haematologica; 2006 Dec; 91(12):1635-43. PubMed ID: 17145600
    [Abstract] [Full Text] [Related]

  • 5. Renal involvement in systemic amyloidosis: an Italian collaborative study on survival and renal outcome.
    Bergesio F, Ciciani AM, Manganaro M, Palladini G, Santostefano M, Brugnano R, Di Palma AM, Gallo M, Rosati A, Tosi PL, Salvadori M, Immunopathology Group of the Italian Society of Nephrology.
    Nephrol Dial Transplant; 2008 Mar; 23(3):941-51. PubMed ID: 17951308
    [Abstract] [Full Text] [Related]

  • 6. [Complete remission of nephrotic syndrome and improvement of renal function in a patient with light chain deposition disease following high dose chemotherapy with transplantation of autologous haematopoietic stem cells. A case study and review of literature].
    Adam Z, Krejcí M, Pour L, Stepánková S, Cermáková Z, Voska L, Teplan V, Krivanová A, Hájek R, Mayer J.
    Vnitr Lek; 2009 Nov; 55(11):1089-96. PubMed ID: 20017442
    [Abstract] [Full Text] [Related]

  • 7. Autologous stem-cell transplantation in progressing amyloidosis is associated with severe transplant-related toxicity.
    Worel N, Schulenburg A, Mitterbauer M, Keil F, Rabitsch W, Kalhs P, Gisslinger H, Raderer M, Geissler K, Höcker P, Zielinski CC, Oberbauer R, Greinix HT.
    Wien Klin Wochenschr; 2006 Feb; 118(1-2):49-53. PubMed ID: 16489526
    [Abstract] [Full Text] [Related]

  • 8. Short and long-term outcome of treatment with high-dose melphalan and stem cell transplantation for multiple myeloma-associated AL amyloidosis.
    Girnius S, Seldin DC, Skinner M, Finn KT, Quillen K, Doros G, Sanchorawala V.
    Ann Hematol; 2010 Jun; 89(6):579-84. PubMed ID: 20012043
    [Abstract] [Full Text] [Related]

  • 9. Serum free light-chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosis.
    Sanchorawala V, Seldin DC, Magnani B, Skinner M, Wright DG.
    Bone Marrow Transplant; 2005 Oct; 36(7):597-600. PubMed ID: 16044137
    [Abstract] [Full Text] [Related]

  • 10. Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate.
    Gertz MA, Lacy MQ, Dispenzieri A, Ansell SM, Elliott MA, Gastineau DA, Inwards DJ, Micallef IN, Porrata LF, Tefferi A, Litzow MR.
    Bone Marrow Transplant; 2004 Dec; 34(12):1025-31. PubMed ID: 15516945
    [Abstract] [Full Text] [Related]

  • 11. High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study.
    Perz JB, Schonland SO, Hundemer M, Kristen AV, Dengler TJ, Zeier M, Linke RP, Ho AD, Goldschmidt H.
    Br J Haematol; 2004 Dec; 127(5):543-51. PubMed ID: 15566357
    [Abstract] [Full Text] [Related]

  • 12. Long-term outcome of autologous stem cell transplantation in light chain deposition disease.
    Lorenz EC, Gertz MA, Fervenza FC, Dispenzieri A, Lacy MQ, Hayman SR, Gastineau DA, Leung N.
    Nephrol Dial Transplant; 2008 Jun; 23(6):2052-7. PubMed ID: 18178602
    [Abstract] [Full Text] [Related]

  • 13. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis.
    Jaccard A, Moreau P, Leblond V, Leleu X, Benboubker L, Hermine O, Recher C, Asli B, Lioure B, Royer B, Jardin F, Bridoux F, Grosbois B, Jaubert J, Piette JC, Ronco P, Quet F, Cogne M, Fermand JP, Myélome Autogreffe (MAG) and Intergroupe Francophone du Myélome (IFM) Intergroup.
    N Engl J Med; 2007 Sep 13; 357(11):1083-93. PubMed ID: 17855669
    [Abstract] [Full Text] [Related]

  • 14. Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial.
    Cohen AD, Zhou P, Chou J, Teruya-Feldstein J, Reich L, Hassoun H, Levine B, Filippa DA, Riedel E, Kewalramani T, Stubblefield MD, Fleisher M, Nimer S, Comenzo RL.
    Br J Haematol; 2007 Oct 13; 139(2):224-33. PubMed ID: 17897298
    [Abstract] [Full Text] [Related]

  • 15. [Therapy options in systemic AL-amyloidosis with renal involvement].
    Hetzel GR, Schneider P, Mondry A, Heering P, Heyll A, Grabensee B.
    Dtsch Med Wochenschr; 2000 Aug 25; 125(34-35):997-1002. PubMed ID: 11004911
    [Abstract] [Full Text] [Related]

  • 16. [High-dose treatment of systemic AL-amyloidosis with autologous stem cell support].
    Schjesvold FH, Sjo M, Tangen JM, Hammerstrøm J, Brinch L.
    Tidsskr Nor Laegeforen; 2008 Jun 12; 128(12):1392-6. PubMed ID: 18552900
    [Abstract] [Full Text] [Related]

  • 17. Tandem cycles of high-dose melphalan and autologous stem cell transplantation increases the response rate in AL amyloidosis.
    Sanchorawala V, Wright DG, Quillen K, Finn KT, Dember LM, Berk JL, Doros G, Fisher C, Skinner M, Seldin DC.
    Bone Marrow Transplant; 2007 Sep 12; 40(6):557-62. PubMed ID: 17589534
    [Abstract] [Full Text] [Related]

  • 18. Early intensification and autologous stem cell transplantation in patients with systemic AL amyloidosis: a single-centre experience.
    Frossard V, Ketterer N, Rosselet A, Meier P, Cairoli A, Duchosal MA, Kovacsovics T.
    Ann Hematol; 2009 Jul 12; 88(7):681-5. PubMed ID: 19066891
    [Abstract] [Full Text] [Related]

  • 19. Predictive factors for hematopoietic engraftment after autologous peripheral blood stem cell transplantation for AL amyloidosis.
    Oran B, Malek K, Sanchorawala V, Wright DG, Quillen K, Finn KT, La Valley M, Skinner M, Seldin DC.
    Bone Marrow Transplant; 2005 Mar 12; 35(6):567-75. PubMed ID: 15665842
    [Abstract] [Full Text] [Related]

  • 20. Blood stem cell transplantation as therapy for primary systemic amyloidosis (AL).
    Gertz MA, Lacy MQ, Gastineau DA, Inwards DJ, Chen MG, Tefferi A, Kyle RA, Litzow MR.
    Bone Marrow Transplant; 2000 Nov 12; 26(9):963-9. PubMed ID: 11100275
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.